<DOC>
	<DOCNO>NCT00052507</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may interfere growth tumor cell block enzymes necessary cancer cell growth . PURPOSE : Phase II trial study effectiveness bortezomib treat patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Bortezomib Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy bortezomib , term response rate stable disease rate , patient recurrent metastatic colorectal cancer . - Determine toxicity drug patient . - Determine time progression response duration patient treat drug . - Determine whether relationship level transcription factor NF kappa B HIF-1 alpha clinical outcome patient treat drug . OUTLINE : This open-label study . Patients receive bortezomib IV day 1 , 4 , 8 , 11 . Courses repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 21-41 patient accrue study within 2-4 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma colon rectum incurable conventional therapy Metastatic recurrent disease At least 1 unidimensionally measurable lesion At least 20 mm conventional technique least 10 mm spiral CT scan Disease must accessible biopsy No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy More 3 month Hematopoietic Absolute granulocyte count least 1,500/mm^3 WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.25 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( less 5 time ULN liver metastasis present ) Renal Creatinine great 1.25 time UNL OR Creatinine clearance least 50 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychiatric illness social situation would preclude study compliance No uncontrolled concurrent illness No ongoing active infection No active malignancy within past 3 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix No grade 1 great peripheral neuropathy due prior chemotherapy No significant traumatic injury within past 21 day PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No 1 line prior chemotherapy ( include combination fluorouracil , irinotecan , and/or oxaliplatin ) metastatic disease At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Prior adjuvant chemotherapy allow No concurrent cytotoxic chemotherapy Radiotherapy More 4 week since prior radiotherapy recover No prior radiotherapy measurable target lesion unless disease progression occur radiotherapy No concurrent radiotherapy sole site measurable disease Surgery More 21 day since prior major surgery Other No concurrent investigational agent No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>